MedTrace Logo

Adjunctive 308-nm Excimer Light With Oral Azithromycin for Inflammatory Acne

NCT07777952 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-08-21

No results posted yet for this study

Summary

This randomized, evaluator-blinded, split-face study evaluated whether adjunctive lesion-directed 308-nm excimer light improves inflammatory acne outcomes during oral azithromycin therapy. All participants received oral azithromycin 500 mg three times weekly for 8 weeks. One randomly allocated hemiface additionally received 308-nm excimer light twice weekly for 8 weeks, while the contralateral hemiface served as the azithromycin-only control. Papule and pustule counts and hemiface Investigator's Global Assessment were assessed through Week 8. Investigator's Global Assessment was reassessed at Week 16 after an 8-week treatment-free follow-up. We hypothesized that the excimer-treated hemiface would demonstrate greater reduction in total inflammatory-lesion count by Week 8.

Conditions

  • Acne Vulgaris

Interventions

DEVICE

308-nm Excimer Light

Monochromatic 308-nm excimer light was delivered using the KN-5000C device. Irradiation was lesion-directed and administered twice weekly for 8 weeks, with at least 48 hours between sessions, for a planned total of 16 sessions. Treatment began at 0.15 J/cm² and was increased according to erythema response and device dose settings, up to a maximum of 0.65 J/cm².

DRUG

Azithromycin

Description: Oral azithromycin 500 mg was administered after meals three times weekly for 8 weeks, corresponding to 24 scheduled doses.

Sponsors & Collaborators

  • Mahmoud Rageh

    lead OTHER

Principal Investigators

  • Rabie B Atallah, MD · Al-Azhar University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-12
Primary Completion
2026-03-10
Completion
2026-05-10

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07777952 on ClinicalTrials.gov